H.C. Wainwright analyst Yi Chen raised the firm’s price target on Ocular Therapeutix to $12 from $10 and keeps a Buy rating on the shares. The OTX-TKI 12-month data demonstrated 89% reduction in treatment burden for wet age-related macular degeneration, the analyst tells investors in a research note. The firm believes the data support further development of OTX-TKI as a maintenance therapy for wet AMD patients with well controlled subretinal or intraretinal fluid by prior anti-VEGF therapies.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
- Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
- Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
- Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
- Biotech Alert: Searches spiking for these stocks today